Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Repare Therapeutics Inc
(NQ:
RPTX
)
2.970
-0.040 (-1.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
52,249
Open
3.050
Bid (Size)
2.910 (5)
Ask (Size)
3.300 (33)
Prev. Close
3.010
Today's Range
2.950 - 3.100
52wk Range
2.780 - 13.85
Shares Outstanding
42,088,446
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
August 06, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
June 26, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Performance
YTD
-59.26%
-59.26%
1 Month
-24.43%
-24.43%
3 Month
-4.19%
-4.19%
6 Month
-52.56%
-52.56%
1 Year
-71.25%
-71.25%
More News
Read More
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
June 10, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Recap: Repare Therapeutics Q4 Earnings
February 28, 2024
Via
Benzinga
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
June 04, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
May 29, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Why RingCentral Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
May 08, 2024
Via
Benzinga
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 08, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May 08, 2024
Via
InvestorPlace
RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
May 07, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
April 30, 2024
From
Debiopharm
Via
Business Wire
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
April 30, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
April 26, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
April 15, 2024
Via
Benzinga
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 21, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 15, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
February 29, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Repare Stockholders and Encourages Investors to Contact the Firm
February 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
February 16, 2024
From
Kirby McInerney LLP
Via
Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
February 15, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
February 13, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.